Peptron

087010.KQ

37.28 USD

-2.41

-6.07%

Overview

Last close

37.28 usd

Market cap

571.41M usd

52 week high

59.02 usd

52 week low

5.35 usd

Target price

26.12 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

430.1606

Price/Book Value

42.63

Enterprise Value

806.89M usd

EV/Revenue

432.009

EV/EBITDA

-17.5233

Key financials

Revenue TTM

4.34M usd

Gross Profit TTM

3.33M usd

EBITDA TTM

-8.02M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

41.87B usd

Net debt

N/A usd

About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.